Approval · Notice of Compliance 32346 · 2023
VIIBRYD: Notice of Compliance 32346
Issued December 14, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32346
- Date
- December 14, 2023
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Labelling Only
- Reason
- Safety updates to the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VIIBRYD | Not yet assigned | — |
Medicinal ingredients
- VILAZODONE HYDROCHLORIDE 10 MG per TAB
- VILAZODONE HYDROCHLORIDE 20 MG per TAB
- VILAZODONE HYDROCHLORIDE 40 MG per TAB